There will be blood: targeting tumor vasculature.

摘要

Extradomain B of fibronectin (ED-B FN) is expressed in the vasculature of hematopoietic malignancies and appears to be an effective target for monoclonal antibody- based therapies.Wherever there is cancer, there will be blood and blood vessels to support tumor growth. While the majority of anticancer drugs are designed to directly kill tumor cells, recent strategies are focusing on drugs that indirectly kill cancer cells by targeting the tumor microenvironment and tumor vasculature. This strategy gained a significant boost with the approval of the angiogenesis inhibitor bevacizumab by the Food and Drug Administration (FDA) for the treatment of a variety ofsolid tumors. In addition to angiogenesis inhibitors, which primarily target the vascular endothelial growth factors (VEGFs) and their receptors, novel antivascular agents are currently under development for cancer therapy.